Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pay-For-Delay, REMS Reform Legislation Making (Slow) Progress In House

Executive Summary

CREATES Act gets a hearing, but Judiciary committee members spend much of their time asking questions about basic concepts of FDA review.

You may also be interested in...



Ways And Means Drug Pricing Hearing Emphasizes Repetitive, Years-Old Questions

There was little on specific legislative proposals and a lot of time discussing broad questions that Congress has been asking for years about drug pricing.

US FDA Wants To Predict ANDA Complete Response Responses

Generic industry, FDA discuss potential ways to increase transparency so agency can better estimate when – and even whether – an ANDA receiving a complete response will be returned.

US FDA Wants To Predict ANDA Complete Response Responses

Generic industry, FDA discuss potential ways to increase transparency so agency can better estimate when – and even whether – an ANDA receiving a complete response will be returned.

Related Content

Topics

UsernamePublicRestriction

Register

PS121206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel